The global Angiotensin Converting Enzyme Inhibitors market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
Angiotensin converting enzyme inhibitors (ACE inhibitors) are medications that slow (inhibit) the activity of the enzyme ACE, which decreases the production of angiotensin II.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
The publisher report includes an overview of the development of the Angiotensin Converting Enzyme Inhibitors industry chain, the market status of Coronary Artery Disease (Benazepril (Lotensin), Captopril), Heart Failure (Benazepril (Lotensin), Captopril), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Angiotensin Converting Enzyme Inhibitors.
Regionally, the report analyzes the Angiotensin Converting Enzyme Inhibitors markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Angiotensin Converting Enzyme Inhibitors market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Angiotensin Converting Enzyme Inhibitors market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Angiotensin Converting Enzyme Inhibitors industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Benazepril (Lotensin), Captopril).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Angiotensin Converting Enzyme Inhibitors market.
Regional Analysis: The report involves examining the Angiotensin Converting Enzyme Inhibitors market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Angiotensin Converting Enzyme Inhibitors market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Angiotensin Converting Enzyme Inhibitors:
Company Analysis: Report covers individual Angiotensin Converting Enzyme Inhibitors players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Angiotensin Converting Enzyme Inhibitors This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Coronary Artery Disease, Heart Failure).
Technology Analysis: Report covers specific technologies relevant to Angiotensin Converting Enzyme Inhibitors. It assesses the current state, advancements, and potential future developments in Angiotensin Converting Enzyme Inhibitors areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Angiotensin Converting Enzyme Inhibitors market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Angiotensin Converting Enzyme Inhibitors market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Benazepril (Lotensin)
Captopril
Enalapril (Vasotec)
Fosinopril
Lisinopril (Prinivil, Zestril)
Moexipril
Perindopril
Quinapril (Accupril)
Ramipril (Altace)
Trandolapril
Market segment by Application
Coronary Artery Disease
Heart Failure
Diabetes
Chronic Kidney Diseases
Heart Attacks
Scleroderma
Migraines
Others
Market segment by players, this report covers
Pfizer
AstraZeneca
Novartis AG
Daiichi Sankyo, Inc
Sanofi
Merck
Abbott
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Angiotensin Converting Enzyme Inhibitors product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Angiotensin Converting Enzyme Inhibitors, with revenue, gross margin and global market share of Angiotensin Converting Enzyme Inhibitors from 2019 to 2024.
Chapter 3, the Angiotensin Converting Enzyme Inhibitors competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Angiotensin Converting Enzyme Inhibitors market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Angiotensin Converting Enzyme Inhibitors.
Chapter 13, to describe Angiotensin Converting Enzyme Inhibitors research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 Market Overview
1.1 Product Overview and Scope of Angiotensin Converting Enzyme Inhibitors
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Angiotensin Converting Enzyme Inhibitors by Type
1.3.1 Overview: Global Angiotensin Converting Enzyme Inhibitors Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Angiotensin Converting Enzyme Inhibitors Consumption Value Market Share by Type in 2023
1.3.3 Benazepril (Lotensin)
1.3.4 Captopril
1.3.5 Enalapril (Vasotec)
1.3.6 Fosinopril
1.3.7 Lisinopril (Prinivil, Zestril)
1.3.8 Moexipril
1.3.9 Perindopril
1.3.10 Quinapril (Accupril)
1.3.11 Ramipril (Altace)
1.3.12 Trandolapril
1.4 Global Angiotensin Converting Enzyme Inhibitors Market by Application
1.4.1 Overview: Global Angiotensin Converting Enzyme Inhibitors Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Coronary Artery Disease
1.4.3 Heart Failure
1.4.4 Diabetes
1.4.5 Chronic Kidney Diseases
1.4.6 Heart Attacks
1.4.7 Scleroderma
1.4.8 Migraines
1.4.9 Others
1.5 Global Angiotensin Converting Enzyme Inhibitors Market Size & Forecast
1.6 Global Angiotensin Converting Enzyme Inhibitors Market Size and Forecast by Region
1.6.1 Global Angiotensin Converting Enzyme Inhibitors Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Angiotensin Converting Enzyme Inhibitors Market Size by Region, (2019-2030)
1.6.3 North America Angiotensin Converting Enzyme Inhibitors Market Size and Prospect (2019-2030)
1.6.4 Europe Angiotensin Converting Enzyme Inhibitors Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Angiotensin Converting Enzyme Inhibitors Market Size and Prospect (2019-2030)
1.6.6 South America Angiotensin Converting Enzyme Inhibitors Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Angiotensin Converting Enzyme Inhibitors Market Size and Prospect (2019-2030)
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Angiotensin Converting Enzyme Inhibitors Product and Solutions
2.1.4 Pfizer Angiotensin Converting Enzyme Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 AstraZeneca
2.2.1 AstraZeneca Details
2.2.2 AstraZeneca Major Business
2.2.3 AstraZeneca Angiotensin Converting Enzyme Inhibitors Product and Solutions
2.2.4 AstraZeneca Angiotensin Converting Enzyme Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 AstraZeneca Recent Developments and Future Plans
2.3 Novartis AG
2.3.1 Novartis AG Details
2.3.2 Novartis AG Major Business
2.3.3 Novartis AG Angiotensin Converting Enzyme Inhibitors Product and Solutions
2.3.4 Novartis AG Angiotensin Converting Enzyme Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Novartis AG Recent Developments and Future Plans
2.4 Daiichi Sankyo, Inc
2.4.1 Daiichi Sankyo, Inc Details
2.4.2 Daiichi Sankyo, Inc Major Business
2.4.3 Daiichi Sankyo, Inc Angiotensin Converting Enzyme Inhibitors Product and Solutions
2.4.4 Daiichi Sankyo, Inc Angiotensin Converting Enzyme Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Daiichi Sankyo, Inc Recent Developments and Future Plans
2.5 Sanofi
2.5.1 Sanofi Details
2.5.2 Sanofi Major Business
2.5.3 Sanofi Angiotensin Converting Enzyme Inhibitors Product and Solutions
2.5.4 Sanofi Angiotensin Converting Enzyme Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Sanofi Recent Developments and Future Plans
2.6 Merck
2.6.1 Merck Details
2.6.2 Merck Major Business
2.6.3 Merck Angiotensin Converting Enzyme Inhibitors Product and Solutions
2.6.4 Merck Angiotensin Converting Enzyme Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Merck Recent Developments and Future Plans
2.7 Abbott
2.7.1 Abbott Details
2.7.2 Abbott Major Business
2.7.3 Abbott Angiotensin Converting Enzyme Inhibitors Product and Solutions
2.7.4 Abbott Angiotensin Converting Enzyme Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Abbott Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Angiotensin Converting Enzyme Inhibitors Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Angiotensin Converting Enzyme Inhibitors by Company Revenue
3.2.2 Top 3 Angiotensin Converting Enzyme Inhibitors Players Market Share in 2023
3.2.3 Top 6 Angiotensin Converting Enzyme Inhibitors Players Market Share in 2023
3.3 Angiotensin Converting Enzyme Inhibitors Market: Overall Company Footprint Analysis
3.3.1 Angiotensin Converting Enzyme Inhibitors Market: Region Footprint
3.3.2 Angiotensin Converting Enzyme Inhibitors Market: Company Product Type Footprint
3.3.3 Angiotensin Converting Enzyme Inhibitors Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Angiotensin Converting Enzyme Inhibitors Consumption Value and Market Share by Type (2019-2024)
4.2 Global Angiotensin Converting Enzyme Inhibitors Market Forecast by Type (2025-2030)
5 Market Size Segment by Application
5.1 Global Angiotensin Converting Enzyme Inhibitors Consumption Value Market Share by Application (2019-2024)
5.2 Global Angiotensin Converting Enzyme Inhibitors Market Forecast by Application (2025-2030)
6 North America
6.1 North America Angiotensin Converting Enzyme Inhibitors Consumption Value by Type (2019-2030)
6.2 North America Angiotensin Converting Enzyme Inhibitors Consumption Value by Application (2019-2030)
6.3 North America Angiotensin Converting Enzyme Inhibitors Market Size by Country
6.3.1 North America Angiotensin Converting Enzyme Inhibitors Consumption Value by Country (2019-2030)
6.3.2 United States Angiotensin Converting Enzyme Inhibitors Market Size and Forecast (2019-2030)
6.3.3 Canada Angiotensin Converting Enzyme Inhibitors Market Size and Forecast (2019-2030)
6.3.4 Mexico Angiotensin Converting Enzyme Inhibitors Market Size and Forecast (2019-2030)
7 Europe
7.1 Europe Angiotensin Converting Enzyme Inhibitors Consumption Value by Type (2019-2030)
7.2 Europe Angiotensin Converting Enzyme Inhibitors Consumption Value by Application (2019-2030)
7.3 Europe Angiotensin Converting Enzyme Inhibitors Market Size by Country
7.3.1 Europe Angiotensin Converting Enzyme Inhibitors Consumption Value by Country (2019-2030)
7.3.2 Germany Angiotensin Converting Enzyme Inhibitors Market Size and Forecast (2019-2030)
7.3.3 France Angiotensin Converting Enzyme Inhibitors Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Angiotensin Converting Enzyme Inhibitors Market Size and Forecast (2019-2030)
7.3.5 Russia Angiotensin Converting Enzyme Inhibitors Market Size and Forecast (2019-2030)
7.3.6 Italy Angiotensin Converting Enzyme Inhibitors Market Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Angiotensin Converting Enzyme Inhibitors Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Angiotensin Converting Enzyme Inhibitors Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Angiotensin Converting Enzyme Inhibitors Market Size by Region
8.3.1 Asia-Pacific Angiotensin Converting Enzyme Inhibitors Consumption Value by Region (2019-2030)
8.3.2 China Angiotensin Converting Enzyme Inhibitors Market Size and Forecast (2019-2030)
8.3.3 Japan Angiotensin Converting Enzyme Inhibitors Market Size and Forecast (2019-2030)
8.3.4 South Korea Angiotensin Converting Enzyme Inhibitors Market Size and Forecast (2019-2030)
8.3.5 India Angiotensin Converting Enzyme Inhibitors Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Angiotensin Converting Enzyme Inhibitors Market Size and Forecast (2019-2030)
8.3.7 Australia Angiotensin Converting Enzyme Inhibitors Market Size and Forecast (2019-2030)
9 South America
9.1 South America Angiotensin Converting Enzyme Inhibitors Consumption Value by Type (2019-2030)
9.2 South America Angiotensin Converting Enzyme Inhibitors Consumption Value by Application (2019-2030)
9.3 South America Angiotensin Converting Enzyme Inhibitors Market Size by Country
9.3.1 South America Angiotensin Converting Enzyme Inhibitors Consumption Value by Country (2019-2030)
9.3.2 Brazil Angiotensin Converting Enzyme Inhibitors Market Size and Forecast (2019-2030)
9.3.3 Argentina Angiotensin Converting Enzyme Inhibitors Market Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Angiotensin Converting Enzyme Inhibitors Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Angiotensin Converting Enzyme Inhibitors Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Angiotensin Converting Enzyme Inhibitors Market Size by Country
10.3.1 Middle East & Africa Angiotensin Converting Enzyme Inhibitors Consumption Value by Country (2019-2030)
10.3.2 Turkey Angiotensin Converting Enzyme Inhibitors Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Angiotensin Converting Enzyme Inhibitors Market Size and Forecast (2019-2030)
10.3.4 UAE Angiotensin Converting Enzyme Inhibitors Market Size and Forecast (2019-2030)
11 Market Dynamics
11.1 Angiotensin Converting Enzyme Inhibitors Market Drivers
11.2 Angiotensin Converting Enzyme Inhibitors Market Restraints
11.3 Angiotensin Converting Enzyme Inhibitors Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Angiotensin Converting Enzyme Inhibitors Industry Chain
12.2 Angiotensin Converting Enzyme Inhibitors Upstream Analysis
12.3 Angiotensin Converting Enzyme Inhibitors Midstream Analysis
12.4 Angiotensin Converting Enzyme Inhibitors Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Pfizer
AstraZeneca
Novartis AG
Daiichi Sankyo, Inc
Sanofi
Merck
Abbott
听
听
*If Applicable.
